The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
Experts highlighted the clinical and neurobiological overlap between sleep disturbances and psychiatric conditions at the 2026 NP Institute in Nashville.
Experts highlighted the clinical and neurobiological overlap between sleep disturbances and psychiatric conditions at the 2026 NP Institute in Nashville.
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
In an observational study, solriamfetol was found to reduce cognitive impairment associated with obstructive sleep apnea (OSA), independently of improvements in excessive daytime sleepiness (EDS)
In an observational study, solriamfetol was found to reduce cognitive impairment associated with obstructive sleep apnea (OSA), independently of improvements in excessive daytime sleepiness (EDS)
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
In patients with major depressive disorder with insomnia symptoms (MDDIS), response rates were similarly robust with adjunctive seltorexant and quetiapine extended-release (XR).
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
A new clinical practice guideline from the American Academy of Sleep Medicine recommends significant changes in the treatment of patients with restless leg syndrome (RLS), and updates the academy’s previous guidance from 2012.
A new clinical practice guideline from the American Academy of Sleep Medicine recommends significant changes in the treatment of patients with restless leg syndrome (RLS), and updates the academy’s previous guidance from 2012.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
A narrative review in PLOS Mental Health synthesizes evidence on the bidirectional relationship between sleep and psychiatric disorders and highlights shared neurobiological mechanisms that span major depression, bipolar disorder (BD),...
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
A new clinical practice guideline from the American Academy of Sleep Medicine recommends significant changes in the treatment of patients with restless leg syndrome (RLS), and updates the academy’s previous guidance from 2012.
A new clinical practice guideline from the American Academy of Sleep Medicine recommends significant changes in the treatment of patients with restless leg syndrome (RLS), and updates the academy’s previous guidance from 2012.
Older adults with sleep-related daytime dysfunction, consisting of excessive sleepiness and lower enthusiasm, are at increased risk of developing a predementia syndrome called motoric cognitive risk syndrome, according to a study published in...
Older adults with sleep-related daytime dysfunction, consisting of excessive sleepiness and lower enthusiasm, are at increased risk of developing a predementia syndrome called motoric cognitive risk syndrome, according to a study published in...
Results from a pilot study of patients with narcolepsy provide proof-of-concept evidence that a procedure called targeted lucidity reactivation can be adapted for narcolepsy-related nightmares.
Results from a pilot study of patients with narcolepsy provide proof-of-concept evidence that a procedure called targeted lucidity reactivation can be adapted for narcolepsy-related nightmares.
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression.
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
CBT-i Coach
Click image for app site
This app is the result of a collaborative effort between the US Department of Veterans Affairs’ National Center for PTSD, Stanford School of Medicine, and the US Department of Defense’s National...
CBT-i Coach
Click image for app site
This app is the result of a collaborative effort between the US Department of Veterans Affairs’ National Center for PTSD, Stanford School of Medicine, and the US Department of Defense’s National...
T2 Mood Tracker
Click image for app site
Originally developed as a tool for service members to easily record and review behavior changes particularly after combat deployments, it has now become very popular with many civilian users...
T2 Mood Tracker
Click image for app site
Originally developed as a tool for service members to easily record and review behavior changes particularly after combat deployments, it has now become very popular with many civilian users...
Click here for Medication Adherence Rating Scale (MARS) - page 7
The total score ranges from 0-10 with a higher score indicating better adherence
Strengths
Self-report...
Click here for Medication Adherence Rating Scale (MARS) - page 7
The total score ranges from 0-10 with a higher score indicating better adherence
Strengths
Self-report...
Click here for website for SDS
How to Use
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score
Total score 0-30 (0 unimpaired, 30 highly...
Click here for website for SDS
How to Use
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score
Total score 0-30 (0 unimpaired, 30 highly...
How to Use
The Brief Psychiatric Rating Scale (BPRS) is a comprehensive 24-item symptom scale.
The BPRS is used as part of a clinical interview in which the clinician makes...
How to Use
The Brief Psychiatric Rating Scale (BPRS) is a comprehensive 24-item symptom scale.
The BPRS is used as part of a clinical interview in which the clinician makes...
How to Use
The MINI is a widely used psychiatric structured diagnostic interview instrument.
To keep the interview brief, tell the patient the interview is structured and requires only “yes” or “no” answers.
The MINI...
How to Use
The MINI is a widely used psychiatric structured diagnostic interview instrument.
To keep the interview brief, tell the patient the interview is structured and requires only “yes” or “no” answers.
The MINI...
How to Use
The MINI Screen is a subset (2 pages) of the complete MINI and acts as a tool to refer healthcare providers to the complete MINI.
Click here for the website for the MINI Screen
How to...
How to Use
The MINI Screen is a subset (2 pages) of the complete MINI and acts as a tool to refer healthcare providers to the complete MINI.
Click here for the website for the MINI Screen
How to...
How to Use
The Patient Health Questionnaire (PHQ-9) is a brief, 9-item self-report screening tool that may help identify symptoms that could relate to depression. The PHQ-9 was developed for use in primary care...
How to Use
The Patient Health Questionnaire (PHQ-9) is a brief, 9-item self-report screening tool that may help identify symptoms that could relate to depression. The PHQ-9 was developed for use in primary care...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
Click here for a PDF of the HAM-A
Developed in 1959 by Dr. M. Hamilton, the scale has proven useful not only in following individual patients but also in...
Click here for a PDF of the HAM-A
Developed in 1959 by Dr. M. Hamilton, the scale has proven useful not only in following individual patients but also in...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
